Hepatitis B Vaccine Debate Intensifies as CDC Panel Weighs Birth Dose Recommendation
A critical decision regarding newborn health is looming as a Centers for Disease Control and Prevention (CDC) vaccine advisory panel, appointed by Health and Human Services Secretary Robert F. Kennedy Jr., prepares to discuss and vote on the long-standing recommendation for a hepatitis B birth dose. The meeting, scheduled to begin December 4th, could potentially limit children’s access to this preventative measure, sparking concern among medical professionals.
For decades, liver specialist Brian McMahon, working at a tribal-owned hospital in Anchorage, Alaska, has witnessed the devastating consequences of hepatitis B. Before the introduction of a vaccine in the 1980s, the virus rapidly claimed young lives in western Alaskan communities. McMahon recalls one patient, a 17-year-old poised to graduate as valedictorian, diagnosed with liver cancer caused by hepatitis B just weeks before her ceremony – she tragically passed away before receiving her diploma. He also remembers an 8-year-old boy, initially asymptomatic, who succumbed to a rapidly growing liver tumor, his final words echoing in McMahon’s memory: “I know I am going to die soon.”
The hepatitis B virus, transmitted through even microscopic amounts of blood and bodily fluids, can survive on surfaces for up to a week. McMahon notes that many of his young patients contracted the virus at birth or in early childhood. Fortunately, this outcome is now largely preventable. The birth dose of the hepatitis B vaccine, recommended since 1991, is up to 90% effective in preventing infection from the mother if administered within the first 24 hours of life. Completing the three-dose series provides 98% immunity, lasting for at least 30 years. Years of targeted testing and vaccination in western Alaska have dramatically reduced cases, with McMahon reporting, “Liver cancer has disappeared in children. We haven’t seen a case since 1995. Nor do we have any children under 30 that have gotten infected that we know of.” He fears these gains are now at risk.
Questioning the Birth Dose
The upcoming CDC advisory committee meeting has reignited debate surrounding the hepatitis B birth dose. On a podcast in June, Kennedy falsely asserted that the vaccine is a “likely culprit” of autism and claimed the virus is not easily contagious. However, extensive research demonstrates the virus can be transmitted through indirect contact – sharing personal items like razors or toothbrushes can spread traces of infected fluids.
The committee’s recommendations carry significant weight, influencing insurance coverage and state vaccination policies. While neither the Advisory Committee on Immunization Practices (ACIP) nor the CDC can mandate immunizations – that authority rests with individual states – maintaining the birth dose recommendation ensures families retain the widest range of options. They can choose to vaccinate at birth, delay vaccination, or forgo it altogether, with insurance continuing to cover the cost as long as the vaccine remains FDA-approved.
Recent statements from two senior Food and Drug Administration (FDA) officials – Commissioner Marty Makary and top vaccine regulator Vinay Prasad – suggest potential changes to the vaccine approval process are under consideration. In internal emails obtained by PBS NewsHour and The Washington Post, Prasad questioned the practice of administering multiple vaccines simultaneously, though it remains unclear if this referred to combination vaccines. Currently, three of the nine FDA-approved hepatitis B vaccines are combination vaccines, while the birth dose is administered as a standalone shot. A Health and Human Services spokesperson stated that the ACIP will base its recommendations on “gold standard, evidence-based science and common sense.”
Concerns Over Misinformation
Even if insurers continue to cover the hepatitis B vaccine, experts fear misinformation stemming from the December meeting could dissuade parents from vaccinating their newborns. “Whatever comes out of this disaster of a meeting in December is going to be mainly designed around sowing distrust and spreading fear,” said Sean O’Leary, chair of the Committee on Infectious Diseases for the American Academy of Pediatrics.
President Donald Trump, Kennedy, and some newly appointed ACIP members have misrepresented the spread of hepatitis B, downplaying the risk of indirect transmission. The virus is significantly more infectious than HIV; unvaccinated individuals can contract it from microscopic amounts of blood on surfaces. McMahon has treated children who tested negative at birth but later became infected through such contact, with nearly a third developing chronic hepatitis B in a 1970s study. “It’s a very infectious virus,” McMahon emphasized. “That’s why giving everybody the birth dose is the best way to prevent it.”
The CDC recommends screening all pregnant individuals for hepatitis B, but estimates up to 16% are not tested. Experts note that widespread testing shortly before or after delivery is impractical due to staffing and resource limitations in many hospitals. The three-dose vaccine boasts a strong safety record, with numerous studies showing no increased risk of infant death, fever, sepsis, multiple sclerosis, autoimmune conditions, or severe reactions. “We have an incredible safety profile,” O’Leary stated, drawing a parallel to seatbelt use: “No one expects to get in a car wreck, right? And yet we all put our seat belts on. This is similar.”
The Stakes of Reduced Vaccination
Currently, the CDC estimates 2.4 million Americans live with hepatitis B, half unaware of their infection. The disease can range from acute to chronic, often presenting with few or no symptoms. Untreated, it can lead to cirrhosis, liver failure, and liver cancer – conditions with no cure, though treatment options exist.
Some parents may question the need for a vaccine in healthy newborns, particularly if they believe they are not at risk. William Schaffner, a professor of preventative medicine at Vanderbilt University, advises expectant parents to discuss the vaccine with their doctor. Even with a negative maternal test, the birth dose remains crucial due to the possibility of false negatives and the ease of transmission through surface contact. He highlighted that babies receiving the full vaccine series have an 84% reduced risk of liver cancer. “If you wait a month and if the mom happens to be positive, or the baby picks it up from a caregiver, by that time the infection is established in that baby’s liver,” Schaffner explained. “It’s too late to prevent that infection.” Reduced vaccination rates will inevitably lead to increased circulation of hepatitis B and a heightened risk for those who remain unvaccinated.
Increased hepatitis B cases would also strain healthcare resources. The CDC estimates treating a less severe case costs $25,000 to $94,000 annually, while a liver transplant can exceed $320,000. Over the past 30 years, the most commonly reported adverse events following the birth dose have been mild fussiness and crying. Schaffner reiterated the vaccine’s strong safety profile, noting its widespread adoption in other countries.
This story originates from NPR’s health reporting partnership with KFF Health News, a national newsroom dedicated to in-depth health journalism and a core program of KFF – an independent source of health policy research, polling, and journalism.
